CluePoints earns third Scrip Awards shortlisting in eight years for its risk-based quality management software serving clinical research.

RBQM's $13.8M value driven 84% by Phase III timeline gains, with clinical phase durations shrinking up to 19% in...

Oncolytics Biotech completes GOBLET pancreatic cancer cohort enrollment, advancing pelareorep combination therapy evaluation in metastatic disease.

Edesa Biotech wins FDA clearance to advance EB06, a CXCL10-blocking antibody, into Phase 2 testing for vitiligo treatment.

Jasper Therapeutics completes IgA Nephropathy Phase 2 enrollment for KP104 and plans interim data release by year-end 2026.

FDA's approval of two blood-based Alzheimer's tests signals regulators now accept plasma biomarkers as primary endpoints, reshaping CNS trial...

RBQM's full value exceeds current financial models, with omitted factors like rework reduction and inspection readiness potentially representing more...

Advarra identifies five workflow patterns causing clinical trial activation delays, from duplicate data entry to poor visibility of prerequisites.

Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety trial, showing no statistically significant benefit over placebo.

Entrada Therapeutics reports Phase 1/2 data for ENTR-601-45 in exon 45 skipping, the most common single-exon target affecting 8%...